PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

NCT00838760 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Tibotec Pharmaceuticals, Ireland